EUCTR2011-003339-74-GB进行中（未招募）1 期
A Prospective Randomised Controlled Trial of Intravitreal Ozurdex and Macular Laser Therapy versus Macular Laser Therapy only in Diabetic Macular Oedema (OZLASE study) - OZLASE study
Moorfields Eye Hospital R&D Department0 个研究点目标入组 80 人开始时间: 2011年8月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects of either sex aged 18 years or over 2. Diagnosis of diabetes mellitus (type 1 or type 2). Any one of the following will be considered to be sufficient evidence that diabetes is present: i.Current regular use of insulin for the treatment of diabetes ii.Current regular use of oral anti-hyperglycaemic agents for the treatment of diabetes iii.Documented diabetes by ADA and/or WHO criteria (see Procedures Manual for Diagnosis of Diabetes) 3.Best corrected visual acuity in the study eye between 54 and 78 letters at 1m (ie Snellen VA 6/24 - 6/9) at baseline. 4.On clinical exam, retinal thickening due to diabetic macular oedema involving the centre of the macula and OCT central subfield > 300 microns (Spectralis) at baseline. The diabetic macular oedema must be mild to moderate defined as centre involving with a visual acuity of 6/24 - 6/). 5.Media clarity, pupillary dilation, and subject cooperation sufficient for adequate fundus photographs. 6.Intraocular pressure less than 30 mmHg. 7.Ability to return for study visits 8.Visual acuity in fellow eye = 2/60 9. Ability to give informed consent throughout the duration of the study 10. Previous laser treatment to the macula is not a contraindication to inclusion in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 55
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 25
排除标准
- •The following exclusions apply to the study eye only (i.e. they may be present for the non study eye, provided that inclusion criterion 8 is met): 1.Macular ischaemia (FAZ > 1000µm in diameter or severe perifoveal intercapillary loss on IVFA). 2.Macular oedema is considered to be due to a cause other than diabetic macular oedema. An eye should not be considered eligible if: (1) the macular oedema is considered to be related to cataract extraction or (2) clinical exam and/or OCT suggest that vitreoretinal interface abnormalities disease (e.g., a taut posterior hyaloid or epiretinal membrane) is the primary cause of the macular oedema. 3.Co-existent ocular disease An ocular condition is present such that, in the opinion of the investigator, visual acuity would not improve from resolution of macular oedema (e.g., foveal atrophy, pigmentary changes, dense subfoveal hard exudates, non retinal conditions, such as amblyopia). 4.An ocular condition is present (other than diabetes) that, in the opinion of the investigator,might affect macular oedema or alter visual acuity during the course of the study (e.g.vein occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, Irvine-Gass syndrome, etc). 5.A substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., cataract would be reducing acuity to 6/12 or worse if eye was otherwise normal). 6.History of treatment for DMO at any time in the past 3 months (such as focal/grid macular photocoagulation, intravitreal or peribulbar corticosteroids, anti-VEGF drugs, or any other treatment) in the study eye. 7.History of panretinal scatter photocoagulation (PRP) within 3 months prior to randomisation in the study eye. 8.Anticipated need for PRP in the 6 months following randomisation in the study eye. 9.Proliferative diabetic retinopathy in the study eye. 10.A condition that, in the opinion of the investigator, would preclude participation in the study. 11.Haemoglobin A1c > 11.0 % 12.A past medical history of significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant 13.Blood pressure >170/100 mmHg (i.e. systolic above 170 or diastolic above 100). If blood pressure is brought below 170/100 by anti-hypertensive treatment, subject can become eligible. 14.Major surgery within 28 days prior to randomisation or major surgery planned during the next 12 months at baseline. Major surgery is defined as a surgical procedure that is more extensive than fine needle biopsy/aspiration, placement of a central venous access device, removal/biopsy of a skin lesion, or placement of a peripheral venous catheter. 15.Participation in an investigational trial within 30 days of randomisation that involved treatment with any drug that has not received regulatory approval at the time of study entry. Note: subjects cannot receive another investigational drug while participating in the study. 16.Pregnant or lactating women or women intending to become pregnant within the study period including 3 months after study cessation. 17.History of major ocular surgery (including cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 3 months or anticipated within the next 6 months following randomisation. 18.Aphakia 19.Uncontrolled glaucoma (in investigator’s judgment). 20.Exam evidence of external ocular infection, including conjunctivitis, chalazion, or severe bl
研究者
相似试验
已完成
不适用
A Prospective Randomised Controlled Trial of the Immediate Post-operative Intra-articular Local Anaesthetic Infusion Using Infusion Pump in Total Knee Arthroplasty.Signs and Symptoms: PainSigns and SymptomsPainISRCTN32365985Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)50
招募中
Unknown
Evaluating an In-Person, Clinician-Facilitated and an Online, Guided Self-Help Program for University Students with Social AnxietyMental Health - AnxietySocial Anxiety DisorderACTRN12624000720516Professor Elizabeth Rieger90
进行中（未招募）
不适用
The effect of preemptive intravenous low dose magnesium sulphate on early postoperative pain after laparoscopic cholecystectomyearly postoperative pain after laparoscopic cholecystectomyAnaesthesiology - Pain managementACTRN12609000182291Iva Bacak Kocman60
尚未招募
不适用
Injection of product derived from patient own blood into the knee and assess for improvement in pain and disability in patient suffering from osteoarthritis of kneeCTRI/2022/11/047634Hospital supply
进行中（未招募）
3 期
Randomized controlled trial of the Effect of intraVenous iron on Anaemia in Malawian Pregnant womeSmall for Gestational AgeACTRN12618001268235niversity of Malawi, College of Medicine862